The U.S. Food and Drug Administration (FDA) has granted a crucial accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) by Johnson & Johnson, marking the first major second-line treatment advancement for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in over a decade. Delivered via a rapid, five-minute subcutaneous injection under the skin, this dual-targeted therapy simultaneous blocks the EGFR and MET pathways to halt tumor progression. Clinical trials demonstrated an impressive 42 percent overall response rate in patients whose disease had previously progressed under standard chemotherapy.
About the Author
